2,3-dihydro-naphtho[1,2-b][4,1]oxathiine-5,6-dione | 221129-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2,3-dihydro-naphtho[1,2-b][4,1]oxathiine-5,6-dione
• 英文别名: 2,3-Dihydrobenzo[f][1,4]benzoxathiine-5,6-dione
• CAS: 221129-66-4
• 化学式: C₁₂H₈O₃S
• 分子量: 232.26
• InChiKey: IKVFVLHWIJVHEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,2-萘醌 在 硫酸 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 2,3-dihydro-naphtho[1,2-b][4,1]oxathiine-5,6-dione
  参考文献：
  名称：

  WO2008/66300

  摘要：

  公开号：

文献信息

• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE
  申请人：Kwak Taehwan

  公开号：US20100239674A1

  公开（公告）日：2010-09-23

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种用于治疗和/或预防勃起功能障碍的药物组合物，包括（a）按照式1或式2表示的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS
  申请人：Kwak Taehwan

  公开号：US20100255054A1

  公开（公告）日：2010-10-07

  Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种药物组合物，用于治疗和/或预防再狭窄，包括(a) 一定量的化合物，其化学式为1和2，或其药学上可接受的盐、前药、溶剂或异构体，且具有治疗效果，以及(b) 药学上可接受的载体、稀释剂或赋形剂，或任何其组合。
• METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION
  申请人：KWAK Taehwan

  公开号：US20120114714A1

  公开（公告）日：2012-05-10

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种治疗和/或预防勃起功能障碍的药物组合物，包括（a）公式1或2所代表的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂或其组合。
• PHARMACEUTICAL COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM
  申请人：Jo In Geun

  公开号：US20100062065A1

  公开（公告）日：2010-03-11

  Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.
• PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND
  申请人：Jo In Geun

  公开号：US20100209513A1

  公开（公告）日：2010-08-19

  Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound.